Collegium Pharmaceutical Stock Performance
| COLL Stock | USD 29.50 0.10 0.34% |
Collegium Pharmaceutical has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Collegium Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Collegium Pharmaceutical is expected to be smaller as well. Collegium Pharmaceutical right now shows a risk of 2.32%. Please confirm Collegium Pharmaceutical downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Collegium Pharmaceutical will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Collegium Pharmaceutical are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent essential indicators, Collegium Pharmaceutical is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 0.58 | Five Day Return 0.89 | Year To Date Return 2.69 | Ten Year Return 54.09 | All Time Return 139.22 |
1 | Disposition of 10445 shares by Colleen Tupper of Collegium Pharmaceutical at 30.006 subject to Rule 16b-3 | 03/11/2025 |
2 | Have Collegium Pharmaceutical Insiders Been Selling Stock | 03/13/2025 |
3 | Disposition of 2255 shares by Scott Dreyer of Collegium Pharmaceutical at 30.0049 subject to Rule 16b-3 | 03/14/2025 |
4 | Disposition of 1927 shares by Scott Dreyer of Collegium Pharmaceutical at 30.0005 subject to Rule 16b-3 | 03/20/2025 |
5 | Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicines Annual Meeting | 03/27/2025 |
6 | Collegium Pharmaceutical Non-GAAP EPS of 1.49 beats by 0.04, revenue of 177.8M beats by 4.72M | 05/08/2025 |
7 | Pacer Advisors, Inc. Reduces Stake in Collegium Pharmaceutical Inc | 05/09/2025 |
8 | Collegium Announces 25 Million Accelerated Share Repurchase Program | 05/12/2025 |
9 | Disposition of 1949 shares by Colleen Tupper of Collegium Pharmaceutical at 30.0 subject to Rule 16b-3 | 05/13/2025 |
10 | Insider Trading | 05/15/2025 |
11 | Disposition of 977 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 37.4556 subject to Rule 16b-3 | 05/16/2025 |
12 | Collegium Pharmaceuticals Conservative Accounting Might Explain Soft Earnings | 05/20/2025 |
13 | Judges Must Be Free Chief Justices Big Remark On Collegium System | 06/04/2025 |
| Begin Period Cash Flow | 240 M |
Collegium | Build AI portfolio with Collegium Stock |
Collegium Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 2,891 in Collegium Pharmaceutical on March 7, 2025 and sell it today you would earn a total of 58.00 from holding Collegium Pharmaceutical or generate 2.01% return on investment over 90 days. Collegium Pharmaceutical is currently generating 0.0582% in daily expected returns and assumes 2.3247% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Collegium, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Collegium Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Collegium Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Collegium Pharmaceutical, and traders can use it to determine the average amount a Collegium Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0251
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | COLL | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.32 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 1 99% of assets perform better |
Based on monthly moving average Collegium Pharmaceutical is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Collegium Pharmaceutical by adding it to a well-diversified portfolio.
Collegium Pharmaceutical Fundamentals Growth
Collegium Stock prices reflect investors' perceptions of the future prospects and financial health of Collegium Pharmaceutical, and Collegium Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Collegium Stock performance.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0795 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 1.59 B | ||||
| Shares Outstanding | 32.14 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 4.01 X | ||||
| Price To Sales | 1.41 X | ||||
| Revenue | 631.45 M | ||||
| Gross Profit | 578.22 M | ||||
| EBITDA | 341.7 M | ||||
| Net Income | 69.19 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 859.3 M | ||||
| Debt To Equity | 3.82 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 7.30 X | ||||
| Cash Flow From Operations | 204.98 M | ||||
| Earnings Per Share | 1.22 X | ||||
| Market Capitalization | 939.52 M | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (164 M) | ||||
| Working Capital | (27.25 M) | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
About Collegium Pharmaceutical Performance
By examining Collegium Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Collegium Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Collegium Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 51.08 | 48.52 | |
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.15 | 0.15 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.30 | 0.32 |
Things to note about Collegium Pharmaceutical performance evaluation
Checking the ongoing alerts about Collegium Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Collegium Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Collegium Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from ndtv.com: Judges Must Be Free Chief Justices Big Remark On Collegium System |
- Analyzing Collegium Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Collegium Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Collegium Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Collegium Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Collegium Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Collegium Pharmaceutical's stock. These opinions can provide insight into Collegium Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.90) | Earnings Share 1.22 | Revenue Per Share | Quarterly Revenue Growth 0.227 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.